Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;99(12):1074-7.
doi: 10.1136/archdischild-2014-306366. Epub 2014 Sep 3.

Improving recognition of Duchenne muscular dystrophy: a retrospective case note review

Affiliations
Free PMC article

Improving recognition of Duchenne muscular dystrophy: a retrospective case note review

Henriette J A van Ruiten et al. Arch Dis Child. 2014 Dec.
Free PMC article

Abstract

Background: Over the last 30 years, there has been little improvement in the age of diagnosis of Duchenne muscular dystrophy (DMD) (mean age of 4.5-4.11 years).

Aim: To review the diagnostic process for DMD in boys without a family history in order to identify where delays occur and suggest areas for improvement.

Design: A retrospective case note review.

Setting: A tertiary centre for neuromuscular diseases in England.

Patients: All boys without family history diagnosed with DMD in the last 10 years (n=20).

Outcome measures: Mean age at four key steps in the diagnostic pathway of DMD.

Results: (1) Age at first reported symptoms of DMD was 32.5 (8-72) months (2.7 years). (2) First engagement of a healthcare professional was at 42.9 (10-90) months. (3) Creatine kinase (CK) levels were checked at 50.1 (14-91) months. (4) Diagnosis of DMD was confirmed at 51.7 (16-91) months (4.3 years). The total delay from parental concern to diagnosis was 19.2 (4-50) months (1.6 years).

Conclusions: Our study shows an improvement in the age of diagnosis of DMD although there continues to be a delay in presentation to a health professional and a delay in obtaining a CK test. To reduce these delays, we propose screening for DMD as part of the Child Health Surveillance Programme, in addition to lowering the threshold for CK testing in primary care by promoting a new DMD mnemonic MUSCLE. An earlier diagnosis of DMD will allow timely access to genetic counselling, standards of care and clinical trials.

Keywords: Duchenne muscular dystrophy; Paediatrics; creatine kinase; developmental delay; diagnosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Display of individual delays in diagnostic pathway Duchenne muscular dystrophy (DMD). The X-axis displays each individual boy (n=20). The Y-axis represents the total delay (in months) for each boy from first reported symptoms (time 0 on Y-axis) to diagnosis. This total delay is divided into three parts. The blue part of the column is the delay from first reported symptoms to visiting a health professional (Symp-HP), the red part is the delay from visiting a health professional to the creatine kinase test (HP-CK) and the green part is the delay between CK test and the diagnosis of DMD (CK-Diagn).
Figure 2
Figure 2
Duchenne muscular dystrophy (DMD) screening mnemonic MUSCLE. The mnemonic illustrates the main features of DMD and stresses the importance of early creatine kinase (CK) testing.

Comment in

References

    1. Mendell J, Shilling C, Leslie N, et al. Evidence based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012;71:304–13. - PubMed
    1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77–93. - PubMed
    1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet 2010;9:129–226. - PubMed
    1. Eagle M, Baudouin S, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002;12:926–9. - PubMed
    1. Pichavant C, Aartsma-Rus A, Clemens P, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 2011;19:830–40. - PMC - PubMed

Publication types

Substances